Overview

Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

Status:
Not yet recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

This is a single site, double-blind, placebo-controlled, crossover trial to quantify the effects of combination adjunctive therapy on glycemic control, ketogenesis during insulinopenia, insulin resistance, and diabetes burden and quality of life.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of California, San Diego

Collaborator:

Juvenile Diabetes Research Foundation

Treatments:

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
Volagidemab